vs
Side-by-side financial comparison of DTE Energy (DTE) and Viatris (VTRS). Click either name above to swap in a different company.
DTE Energy is the larger business by last-quarter revenue ($4.4B vs $3.7B, roughly 1.2× Viatris). On growth, DTE Energy posted the faster year-over-year revenue change (28.9% vs 5.0%). Over the past eight quarters, DTE Energy's revenue compounded faster (16.9% CAGR vs 0.5%).
DTE Energy is a Detroit-based diversified energy company involved in the development and management of energy-related businesses and services in the United States and Canada. Its operating units include an electric utility serving 2.2 million customers and a natural gas utility serving 1.3 million customers in Michigan.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
DTE vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.4B | $3.7B |
| Net Profit | $369.0M | — |
| Gross Margin | — | 31.1% |
| Operating Margin | 15.9% | -5.2% |
| Net Margin | 8.3% | — |
| Revenue YoY | 28.9% | 5.0% |
| Net Profit YoY | 26.4% | — |
| EPS (diluted) | $1.78 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.4B | $3.7B | ||
| Q3 25 | $3.5B | $3.7B | ||
| Q2 25 | $3.4B | $3.6B | ||
| Q1 25 | $4.4B | $3.2B | ||
| Q4 24 | $3.4B | $3.5B | ||
| Q3 24 | $2.9B | $3.7B | ||
| Q2 24 | $2.9B | $3.8B | ||
| Q1 24 | $3.2B | $3.7B |
| Q4 25 | $369.0M | — | ||
| Q3 25 | $419.0M | — | ||
| Q2 25 | $229.0M | — | ||
| Q1 25 | $445.0M | — | ||
| Q4 24 | $292.0M | — | ||
| Q3 24 | $477.0M | — | ||
| Q2 24 | $322.0M | — | ||
| Q1 24 | $313.0M | — |
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 35.8% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 38.2% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | 15.9% | -5.2% | ||
| Q3 25 | 17.6% | 4.8% | ||
| Q2 25 | 12.5% | 6.5% | ||
| Q1 25 | 14.1% | -88.9% | ||
| Q4 24 | 16.2% | -5.1% | ||
| Q3 24 | 17.8% | 6.0% | ||
| Q2 24 | 17.5% | -6.3% | ||
| Q1 24 | 16.0% | 5.6% |
| Q4 25 | 8.3% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 6.7% | — | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | 16.4% | — | ||
| Q2 24 | 11.2% | — | ||
| Q1 24 | 9.7% | — |
| Q4 25 | $1.78 | $-0.34 | ||
| Q3 25 | $2.01 | $-0.11 | ||
| Q2 25 | $1.10 | $0.00 | ||
| Q1 25 | $2.14 | $-2.55 | ||
| Q4 24 | $1.41 | $-0.43 | ||
| Q3 24 | $2.30 | $0.08 | ||
| Q2 24 | $1.55 | $-0.27 | ||
| Q1 24 | $1.51 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $208.0M | $1.3B |
| Total DebtLower is stronger | $23.8B | — |
| Stockholders' EquityBook value | $12.3B | $14.7B |
| Total Assets | $54.1B | $37.2B |
| Debt / EquityLower = less leverage | 1.93× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $208.0M | $1.3B | ||
| Q3 25 | $34.0M | $975.3M | ||
| Q2 25 | $32.0M | $566.4M | ||
| Q1 25 | $33.0M | $755.0M | ||
| Q4 24 | $24.0M | $734.8M | ||
| Q3 24 | $969.0M | $1.9B | ||
| Q2 24 | $20.0M | $917.2M | ||
| Q1 24 | $292.0M | $1.0B |
| Q4 25 | $23.8B | — | ||
| Q3 25 | $24.5B | — | ||
| Q2 25 | $22.9B | — | ||
| Q1 25 | $21.8B | — | ||
| Q4 24 | $20.7B | — | ||
| Q3 24 | $20.5B | — | ||
| Q2 24 | $19.3B | — | ||
| Q1 24 | $19.2B | — |
| Q4 25 | $12.3B | $14.7B | ||
| Q3 25 | $12.2B | $15.2B | ||
| Q2 25 | $11.7B | $15.6B | ||
| Q1 25 | $11.9B | $15.7B | ||
| Q4 24 | $11.7B | $18.6B | ||
| Q3 24 | $11.6B | $19.8B | ||
| Q2 24 | $11.1B | $19.5B | ||
| Q1 24 | $11.2B | $20.0B |
| Q4 25 | $54.1B | $37.2B | ||
| Q3 25 | $52.0B | $37.9B | ||
| Q2 25 | $50.2B | $38.4B | ||
| Q1 25 | $49.6B | $38.5B | ||
| Q4 24 | $48.8B | $41.5B | ||
| Q3 24 | $49.8B | $44.8B | ||
| Q2 24 | $47.8B | $45.3B | ||
| Q1 24 | $45.9B | $47.3B |
| Q4 25 | 1.93× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 1.96× | — | ||
| Q1 25 | 1.83× | — | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 1.76× | — | ||
| Q2 24 | 1.74× | — | ||
| Q1 24 | 1.72× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.0B | $815.8M |
| Free Cash FlowOCF − Capex | — | $619.3M |
| FCF MarginFCF / Revenue | — | 16.8% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | 2.84× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.0B | $815.8M | ||
| Q3 25 | $632.0M | $744.9M | ||
| Q2 25 | $709.0M | $219.7M | ||
| Q1 25 | $1.0B | $535.5M | ||
| Q4 24 | $1.1B | $482.7M | ||
| Q3 24 | $758.0M | $826.5M | ||
| Q2 24 | $759.0M | $379.1M | ||
| Q1 24 | $1.0B | $614.6M |
| Q4 25 | — | $619.3M | ||
| Q3 25 | — | $658.1M | ||
| Q2 25 | — | $166.8M | ||
| Q1 25 | — | $492.9M | ||
| Q4 24 | — | $342.3M | ||
| Q3 24 | — | $749.5M | ||
| Q2 24 | — | $320.3M | ||
| Q1 24 | — | $564.8M |
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 15.2% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | — | 20.1% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | — | 15.5% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | 2.84× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 3.10× | — | ||
| Q1 25 | 2.29× | — | ||
| Q4 24 | 3.71× | — | ||
| Q3 24 | 1.59× | — | ||
| Q2 24 | 2.36× | — | ||
| Q1 24 | 3.33× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DTE
| Electric Segment | $1.8B | 40% |
| Residential | $723.0M | 16% |
| Gas Segment | $651.0M | 15% |
| Commercial | $524.0M | 12% |
| Other | $333.0M | 8% |
| DTE Vantage Segment | $176.0M | 4% |
| Industrial | $159.0M | 4% |
| End User Transportation | $69.0M | 2% |
| Intermediate Transportation | $25.0M | 1% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
